Which has higher earnings and valuation, PEPG or VALN?

PepGen has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A Valneva $156.33M 3.10 -$130.33M -$1.87 N/A

Is PEPG or VALN more profitable?

PepGen has a net margin of 0.00% compared to Valneva's net margin of -88.87%. PepGen's return on equity of -59.89% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Valneva -88.87% -107.63% -33.02%

Does the media favor PEPG or VALN?

In the previous week, PepGen had 1 more articles in the media than Valneva. MarketBeat recorded 2 mentions for PepGen and 1 mentions for Valneva. PepGen's average media sentiment score of 1.04 beat Valneva's score of 1.02 indicating that PepGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, PEPG or PROK?

ProKidney has higher revenue and earnings than PepGen. ProKidney is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A ProKidney $890K 527.76 -$68.99M -$0.53 N/A

Is PEPG or PROK more profitable?

PepGen has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% ProKidney -8,131.50% N/A -21.39%

Does the media refer more to PEPG or PROK?

In the previous week, PepGen had 1 more articles in the media than ProKidney. MarketBeat recorded 2 mentions for PepGen and 1 mentions for ProKidney. PepGen's average media sentiment score of 1.04 beat ProKidney's score of -0.21 indicating that PepGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, AGMB or PEPG?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A N/A N/A N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is AGMB or PEPG more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A PepGen N/A -59.89% -49.62%

Does the media prefer AGMB or PEPG?

In the previous week, PepGen had 1 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 2 mentions for PepGen and 1 mentions for AgomAb Therapeutics. PepGen's average media sentiment score of 1.04 beat AgomAb Therapeutics' score of 0.00 indicating that PepGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PepGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, PEPG or IMMX?

Immix Biopharma is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A Immix Biopharma N/A N/A -$29.44M -$0.92 N/A

Is PEPG or IMMX more profitable?

PepGen's return on equity of -59.89% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Immix Biopharma N/A -73.24% -59.20%

Does the media favor PEPG or IMMX?

In the previous week, PepGen and PepGen both had 2 articles in the media. PepGen's average media sentiment score of 1.04 beat Immix Biopharma's score of 0.00 indicating that PepGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, RZLT or PEPG?

Rezolute is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is RZLT or PEPG more profitable?

Rezolute's return on equity of -58.82% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% PepGen N/A -59.89% -49.62%

Does the media refer more to RZLT or PEPG?

In the previous week, Rezolute and Rezolute both had 2 articles in the media. PepGen's average media sentiment score of 1.04 beat Rezolute's score of 0.00 indicating that PepGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PepGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PepGen (PEPG) Competitors

$1.88 +0.12 (+6.53%)

As of 03:37 PM Eastern

Compare

PEPG vs. VALN, PROK, AGMB, IMMX, and RZLT

Should you buy PepGen stock or one of its competitors? MarketBeat compares PepGen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PepGen include Valneva (VALN), ProKidney (PROK), AgomAb Therapeutics (AGMB), Immix Biopharma (IMMX), and Rezolute (RZLT). These companies are all part of the "biotechnology" industry.

How does PepGen compare to Valneva?

PepGen (NASDAQ:PEPG) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

PepGen has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market. Comparatively, Valneva has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

PepGen has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Valneva	$156.33M	3.10	-$130.33M	-$1.87	N/A

In the previous week, PepGen had 1 more articles in the media than Valneva. MarketBeat recorded 2 mentions for PepGen and 1 mentions for Valneva. PepGen's average media sentiment score of 1.04 beat Valneva's score of 1.02 indicating that PepGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PepGen has a net margin of 0.00% compared to Valneva's net margin of -88.87%. PepGen's return on equity of -59.89% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Valneva	-88.87%	-107.63%	-33.02%

58.0% of PepGen shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PepGen currently has a consensus target price of $11.50, suggesting a potential upside of 510.08%. Valneva has a consensus target price of $11.98, suggesting a potential upside of 134.34%. Given PepGen's stronger consensus rating and higher possible upside, analysts clearly believe PepGen is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

PepGen beats Valneva on 12 of the 15 factors compared between the two stocks.

How does PepGen compare to ProKidney?

PepGen (NASDAQ:PEPG) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, PepGen had 1 more articles in the media than ProKidney. MarketBeat recorded 2 mentions for PepGen and 1 mentions for ProKidney. PepGen's average media sentiment score of 1.04 beat ProKidney's score of -0.21 indicating that PepGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

ProKidney has higher revenue and earnings than PepGen. ProKidney is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
ProKidney	$890K	527.76	-$68.99M	-$0.53	N/A

PepGen has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

58.0% of PepGen shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

PepGen presently has a consensus price target of $11.50, suggesting a potential upside of 510.08%. ProKidney has a consensus price target of $12.00, suggesting a potential upside of 671.70%. Given ProKidney's higher possible upside, analysts plainly believe ProKidney is more favorable than PepGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

PepGen has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
ProKidney	-8,131.50%	N/A	-21.39%

Summary

PepGen and ProKidney tied by winning 8 of the 16 factors compared between the two stocks.

How does PepGen compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

AgomAb Therapeutics' return on equity of 0.00% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
PepGen	N/A	-59.89%	-49.62%

AgomAb Therapeutics currently has a consensus price target of $33.00, suggesting a potential upside of 146.45%. PepGen has a consensus price target of $11.50, suggesting a potential upside of 510.08%. Given PepGen's higher probable upside, analysts clearly believe PepGen is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, PepGen had 1 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 2 mentions for PepGen and 1 mentions for AgomAb Therapeutics. PepGen's average media sentiment score of 1.04 beat AgomAb Therapeutics' score of 0.00 indicating that PepGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

58.0% of PepGen shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

PepGen beats AgomAb Therapeutics on 6 of the 9 factors compared between the two stocks.

How does PepGen compare to Immix Biopharma?

PepGen (NASDAQ:PEPG) and Immix Biopharma (NASDAQ:IMMX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

58.0% of PepGen shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Comparatively, 30.3% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Immix Biopharma is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

PepGen presently has a consensus target price of $11.50, suggesting a potential upside of 510.08%. Immix Biopharma has a consensus target price of $20.71, suggesting a potential upside of 147.63%. Given PepGen's stronger consensus rating and higher probable upside, analysts plainly believe PepGen is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

PepGen's return on equity of -59.89% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Immix Biopharma	N/A	-73.24%	-59.20%

PepGen has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the broader market.

In the previous week, PepGen and PepGen both had 2 articles in the media. PepGen's average media sentiment score of 1.04 beat Immix Biopharma's score of 0.00 indicating that PepGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PepGen beats Immix Biopharma on 8 of the 12 factors compared between the two stocks.

How does PepGen compare to Rezolute?

Rezolute (NASDAQ:RZLT) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 1.3% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rezolute currently has a consensus price target of $9.38, indicating a potential upside of 93.50%. PepGen has a consensus price target of $11.50, indicating a potential upside of 510.08%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Rezolute's return on equity of -58.82% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
PepGen	N/A	-59.89%	-49.62%

Rezolute is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

In the previous week, Rezolute and Rezolute both had 2 articles in the media. PepGen's average media sentiment score of 1.04 beat Rezolute's score of 0.00 indicating that PepGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rezolute has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, PepGen has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

Summary

Rezolute and PepGen tied by winning 6 of the 12 factors compared between the two stocks.

Get PepGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PEPG vs. The Competition

Export

Metric	PepGen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$130.39M	$3.51B	$6.81B	$12.70B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-1.08	7.34	281.58	25.14
Price / Sales	N/A	1,195.82	571.14	79.78
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	0.88	16.87	11.03	6.20
Net Income	-$89.65M	-$12.54M	$3.48B	$347.60M
7 Day Performance	-0.79%	-0.83%	0.47%	0.81%
1 Month Performance	7.10%	-7.59%	-4.24%	-3.65%
1 Year Performance	42.80%	48.80%	63.03%	20.30%

PepGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PEPG PepGen	3.0991 of 5 stars	$1.89 +7.1%	$11.50 +510.1%	+33.3%	$130.39M	N/A	N/A	30	Upcoming Earnings
VALN Valneva	2.8538 of 5 stars	$5.02 -1.4%	$11.98 +138.6%	-31.2%	$476.23M	$156.33M	N/A	700	Positive News Gap Up
PROK ProKidney	1.6533 of 5 stars	$1.53 -3.5%	$12.00 +686.9%	-45.4%	$460.64M	$890K	N/A	3
AGMB AgomAb Therapeutics	N/A	$12.71 -0.4%	$33.00 +159.7%	N/A	$460.39M	N/A	N/A	62	Lockup Expiration
IMMX Immix Biopharma	2.3623 of 5 stars	$8.36 -2.3%	$20.71 +147.9%	+214.0%	$453.40M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PEPG) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PepGen (PEPG) Competitors